Influenza Vaccine Market Size, Share & Trends Analysis Report By Vaccine Type (Inactivated, Live Attenuated), By Indication, By Age Group, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

Influenza Vaccine Market Size, Share & Trends Analysis Report By Vaccine Type (Inactivated, Live Attenuated), By Indication, By Age Group, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030


Influenza Vaccine Market Growth & Trends

The global influenza vaccine market size is expected to reach USD 12.58 billion by 2030 and is set to expand at 6.98% CAGR from 2024 to 2030, according to a new report by Grand View Research, Inc. The increase in immunization programs, rising awareness regarding flu and influenza, and surge in R&D activities pertaining to flu vaccines are anticipated to propel market growth. In addition, the inclusion of the influenza vaccine in various national immunization programs and increasing awareness programs for immunizations across the globe is anticipated to boost the market growth.

The ongoing influenza vaccination national schemes globally are anticipated to propel the market. For instance, programs such as Universal Influenza Immunization Program and NIP Vaccination Programs among others are some of the key immunization programs. These offer flu vaccines free of cost to all the target population. The key objective of such programs is to eliminate the risk of flu-like disorders.

Trivalent and Quadrivalent vaccines are commercially available influenza vaccines. Among these, the quadrivalent vaccines are the most preferred type owing to their high efficacy and their ability to combat two influenza-B viruses and two influenza-A viruses. Leading companies are undertaking efforts to conduct research studies for quadrivalent product development. For instance, in November 2022, Pfizer Inc. and BioNTech SE announced the advancement of an mRNA-based combination vaccine candidate for COVID-19 and influenza to mitigate two life-threatening respiratory conditions.

Moreover, due to the emergence of new strains, scientists are devising a vaccination strategy that could prevent the flu virus with multiple strains and achieve long-lasting immunity in an individual. For instance, in March 2022, scientists from Monash University, Melbourne, and the National University of Singapore published research in the ‘Proceedings of the National Academy of Sciences’. This research featured a platform to efficiently offer vaccine candidate M2e to the immune cells to attain long-lasting immunity against different virus strains.

Furthermore, various initiatives undertaken by leading market participants are likely to provide exponential growth opportunities for the market. For instance, in February 2020, Abbott announced the launch of inactivated quadrivalent vaccine for protection against four virus strains in India. In addition, in January 2021, ModernaTX, Inc. announced the company’s plans to use mRNA technology to manufacture and develop Nipah, HIV, and flu virus vaccines.

Influenza Vaccine Market Report Highlights
  • Inactivated vaccines held the largest market share of 91.94% in 2023 and are anticipated to grow at the fastest rate during the forecast period.
  • The quadrivalent segment dominated the market with a share of 86.77% in 2023 and is expected to grow at the fastest growth rate over the forecast period. The growth is due to high efficacy against viral infections, cost-effectiveness, and easy availability in clinics & hospitals.
  • The adult segment held the largest revenue share of 78.64% in 2023 owing to favorable efforts to increase immunization and high vaccine dose procurement by UNICEF, GAVI, and PAHO.
  • The injection segment held the largest revenue share of 92.09% in 2023. High growth of the segment accounted for a large number of intramuscular vaccine candidates available in market.
  • Hospitals & pharmacies captured the largest revenue share of 54.00% in 2023. Large quantity of vaccine supply from hospitals is anticipated to generate lucrative revenue opportunities for the segment.
  • North America led the market with a 53.35% share due to rapid launch of effective products along with technologically advanced vaccine production facilities across the region.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 List Of Secondary Sources
1.8 Objectives
1.8.1 Objective 1
1.8.2 Objective 2
1.8.3 Objective 3
1.8.4 Objective 4
1.9 List Of Abbreviations
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Vaccine Type And Indication Snapshot
2.3 Age Group And Route Of Administration Snapshot
2.4 Distribution Channel Snapshot
2.5 Competitive Landscape Snapshot
Chapter 3 Influenza Vaccines Market - Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Biologics Market
3.1.2 Vaccine Market
3.1.3 Related/Ancillary Market Outlook (Meningococcal Vaccines Market)
3.2 Penetration & Growth Prospect Mapping For Vaccine Type, 2022
3.3 Market Dynamics
3.3.1 Market Drivers
3.3.1.1 Increase In Prevalence Of Influenza
3.3.1.2 Active Government Support To Promote Vaccination
3.3.1.3 Strategic Initiatives Undertaken By Leading Players
3.3.2 Market Restraint Analysis
3.3.2.1 High Cost Associated With Storage And Supply of Vaccines
3.3.2.2 Longer Timeline for Vaccine Production
3.4 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
3.5 Industry Analysis - Porter’s
3.6 Pipeline Analysis
3.7 Pricing Analysis
3.8 Vaccination Rate, by Country
Chapter 4 Vaccine Type Business Analysis
4.1 Influenza Vaccine Market: Vaccine Type Movement Analysis
4.2 Influenza Vaccine Market Estimates & Forecast, By Type (USD Million)
4.2.1 Inactivated
4.2.2 Live Attenuated
Chapter 5 Indication Business Analysis
5.1 Influenza Vaccine Market: Indication Movement Analysis
5.2 Influenza Vaccine Market Estimates & Forecast, By Indication (USD Million)
5.2.1 Quadrivalent
5.2.2 Trivalent
Chapter 6 Age Group Business Analysis
6.1 Influenza Vaccine Market: Age Group Movement Analysis
6.2 Influenza Vaccine Market Estimates & Forecast, By Age Group (USD Million)
6.2.1 Pediatric
6.2.2 Adults
Chapter 7 Route Of Administration Business Analysis
7.1 Influenza Vaccine Market: Route of Administration Movement Analysis
7.2 Influenza Vaccine Market Estimates & Forecast, By Route of Administration (USD Million)
7.2.1 Injection
7.2.2 Nasal Spray
Chapter 8 Distribution Channel Business Analysis
8.1 Influenza Vaccine Market: Distribution Channel Movement Analysis
8.2 Influenza Vaccine Market Estimates & Forecast, By Distribution Channel (USD Million)
8.2.1 Hospitals & Pharmacies
8.2.2 Government And Institutional Supply
8.2.3 Others
Chapter 9 Influenza Vaccine Market: Regional Estimates and Trend Analysis, By Vaccine Type, Indication, Age Group, Route of Administration, and Distribution Channel
9.1 Influenza Vaccine Market: Regional Outlook
9.2 North America
9.2.1 North America Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.2.2 U.S.
9.2.2.1 Key Country Dynamics
9.2.2.2 U.S. Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.2.2.3 Competitive Scenario
9.2.2.4 Regulatory Framework
9.2.2.5 Reimbursement Scenario
9.2.3 Canada
9.2.3.1 Key Country Dynamics
9.2.3.2 Canada Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.2.3.3 Competitive Scenario
9.2.3.4 Regulatory Framework
9.2.3.5 Reimbursement Scenario
9.3 Europe
9.3.1 Europe Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.3.2 UK
9.3.2.1 Key Country Dynamics
9.3.2.2 UK Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.3.2.3 Competitive Scenario
9.3.2.4 Regulatory Framework
9.3.2.5 Reimbursement Scenario
9.3.3 Germany
9.3.3.1 Key Country Dynamics
9.3.3.2 Germany Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.3.3.3 Competitive Scenario
9.3.3.4 Regulatory Framework
9.3.3.5 Reimbursement Scenario
9.3.4 France
9.3.4.1 Key Country Dynamics
9.3.4.2 France Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.3.4.3 Competitive Scenario
9.3.4.4 Regulatory Framework
9.3.4.5 Reimbursement Scenario
9.3.5 Spain
9.3.5.1 Key Country Dynamics
9.3.5.2 Spain Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.3.5.3 Competitive Scenario
9.3.5.4 Regulatory Framework
9.3.5.5 Reimbursement Scenario
9.3.6 Italy
9.3.6.1 Key Country Dynamics
9.3.6.2 Italy Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.3.6.3 Competitive Scenario
9.3.6.4 Regulatory Framework
9.3.6.5 Reimbursement Scenario
9.3.7 Denmark
9.3.7.1 Key Country Dynamics
9.3.7.2 Denmark Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.3.7.3 Competitive Scenario
9.3.7.4 Regulatory Framework
9.3.7.5 Reimbursement Scenario
9.3.8 Sweden
9.3.8.1 Key Country Dynamics
9.3.8.2 Sweden Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.3.8.3 Competitive Scenario
9.3.8.4 Regulatory Framework
9.3.8.5 Reimbursement Scenario
9.3.9 Norway
9.3.9.1 Key Country Dynamics
9.3.9.2 Norway Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.3.9.3 Competitive Scenario
9.3.9.4 Regulatory Framework
9.3.9.5 Reimbursement Scenario
9.3.9.6 Rest Of Europe Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.4 Asia Pacific
9.4.1 Asia Pacific Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.4.2 Japan
9.4.2.1 Key Country Dynamics
9.4.2.2 Japan Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.4.2.3 Competitive Scenario
9.4.2.4 Regulatory Framework
9.4.2.5 Reimbursement Scenario
9.4.3 China
9.4.3.1 Key Country Dynamics
9.4.3.2 China Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.4.3.3 Competitive Scenario
9.4.3.4 Regulatory Framework
9.4.3.5 Reimbursement Scenario
9.4.4 India
9.4.4.1 Key Country Dynamics
9.4.4.2 India Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.4.4.3 Competitive Scenario
9.4.4.4 Regulatory Framework
9.4.4.5 Reimbursement Scenario
9.4.5 Australia
9.4.5.1 Key Country Dynamics
9.4.5.2 Australia Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.4.5.3 Competitive Scenario
9.4.5.4 Regulatory Framework
9.4.5.5 Reimbursement Scenario
9.4.6 Thailand
9.4.6.1 Key Country Dynamics
9.4.6.2 Thailand Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.4.6.3 Competitive Scenario
9.4.6.4 Regulatory Framework
9.4.6.5 Reimbursement Scenario
9.4.7 South Korea
9.4.7.1 Key Country Dynamics
9.4.7.2 South Korea Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.4.7.3 Competitive Scenario
9.4.7.4 Regulatory Framework
9.4.7.5 Reimbursement Scenario
9.4.7.6 Rest Of Asia Pacific Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.5 Latin America
9.5.1 Latin America Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.5.2 Brazil
9.5.2.1 Key Country Dynamics
9.5.2.2 Brazil Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.5.2.3 Competitive Scenario
9.5.2.4 Regulatory Framework
9.5.2.5 Reimbursement Scenario
9.5.3 Mexico
9.5.3.1 Key Country Dynamics
9.5.3.2 Mexico Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.5.3.3 Competitive Scenario
9.5.3.4 Regulatory Framework
9.5.3.5 Reimbursement Scenario
9.5.4 Argentina
9.5.4.1 Key Country Dynamics
9.5.4.2 Argentina Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.5.4.3 Competitive Scenario
9.5.4.4 Regulatory Framework
9.5.4.5 Reimbursement Scenario
9.5.4.6 Rest Of Latin America Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.6 MEA
9.6.1 MEA Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.6.2 South Africa
9.6.2.1 Key Country Dynamics
9.6.2.2 South Africa Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.6.2.3 Competitive Scenario
9.6.2.4 Regulatory Framework
9.6.2.5 Reimbursement Scenario
9.6.3 Saudi Arabia
9.6.3.1 Key Country Dynamics
9.6.3.2 Saudi Arabia Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.6.3.3 Competitive Scenario
9.6.3.4 Regulatory Framework
9.6.3.5 Reimbursement Scenario
9.6.4 UAE
9.6.4.1 Key Country Dynamics
9.6.4.2 UAE Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.6.4.3 Competitive Scenario
9.6.4.4 Regulatory Framework
9.6.4.5 Reimbursement Scenario
9.6.5 Kuwait
9.6.5.1 Key Country Dynamics
9.6.5.2 Kuwait Influenza Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.5.3 Competitive Scenario
9.6.5.4 Regulatory Framework
9.6.5.5 Reimbursement Scenario
9.6.5.6 Rest of MEA Influenza Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 10 Competitive Landscape
10.1 Company Categorization
10.2 Participant’s Overview
10.3 Financial Performance
10.4 Product Benchmarking
10.5 Company Market Positioning
10.6 Company Profiles
10.6.1 GSK plc
10.6.1.1 Company overview
10.6.1.2 Financial performance
10.6.1.3 Product benchmarking
10.6.1.4 Strategic Initiatives
10.6.2 AstraZeneca
10.6.2.1 Company overview
10.6.2.2 Financial performance
10.6.2.3 Product benchmarking
10.6.2.4 Strategic Initiatives
10.6.3 SINOVAC
10.6.3.1 Company overview
10.6.3.2 Financial performance
10.6.3.3 Product benchmarking
10.6.3.4 Strategic Initiatives
10.6.4 Vaxess Technologies Inc
10.6.4.1 Company overview
10.6.4.2 Financial performance
10.6.4.3 Product benchmarking
10.6.4.4 Strategic Initiatives
10.6.5 Pfizer Inc
10.6.5.1 Company overview
10.6.5.2 Financial performance
10.6.5.3 Product benchmarking
10.6.5.4 Strategic Initiatives
10.6.6 CSL Limited
10.6.6.1 Company overview
10.6.6.2 Financial performance
10.6.6.3 Product benchmarking
10.6.6.4 Strategic Initiatives
10.6.7 EMERGENT
10.6.7.1 Company overview
10.6.7.2 Financial performance
10.6.7.3 Product benchmarking
10.6.7.4 Strategic initiatives
10.6.8 Merck & Co., Inc.
10.6.8.1 Company overview
10.6.8.2 Financial performance
10.6.8.3 Product benchmarking
10.6.8.4 Strategic initiatives
10.6.9 Viatris Inc.
10.6.9.1 Company overview
10.6.9.2 Financial performance
10.6.9.3 Product benchmarking
10.6.9.4 Strategic initiatives
10.6.10 OSIVAX, EMERGEX VACCINES
10.6.10.1 Company overview
10.6.10.2 Financial performance
10.6.10.3 Product benchmarking
10.6.10.4 Strategic initiatives
10.7 Company Market Share Analysis, 2022
10.8 Company Heat Map Analysis
10.9 Strategy Mapping
10.9.1 Expansion
10.9.2 Collaborations
10.9.3 Partnership
10.9.4 New Product Launches
10.9.5 Others
Chapter 11 Conclusion

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings